Equities

Theravance Biopharma Inc

Theravance Biopharma Inc

Actions
  • Price (EUR)8.25
  • Today's Change0.150 / 1.85%
  • Shares traded0.00
  • 1 Year change-14.06%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments102327173
Total Receivables, Net171758
Total Inventory------
Prepaid expenses149.2019
Other current assets, total------
Total current assets134353250
Property, plant & equipment, net455253
Goodwill, net------
Intangibles, net------
Long term investments--068
Note receivable - long term------
Other long term assets2022013.23
Total assets382607375
LIABILITIES
Accounts payable1.521.553.10
Accrued expenses172738
Notes payable/short-term debt000
Current portion long-term debt/capital leases--017
Other current liabilities, total6.490.020.10
Total current liabilities252959
Total long term debt2825599
Total debt2825616
Deferred income tax------
Minority interest------
Other liabilities, total11611155
Total liabilities169166713
SHAREHOLDERS EQUITY
Common stock00.000.00
Additional paid-in capital1,1221,2961,387
Retained earnings (accumulated deficit)(909)(854)(1726)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.07)(0.02)0
Total equity213442(339)
Total liabilities & shareholders' equity382607375
Total common shares outstanding486574
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.